A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs

Vaccine

Volumn 29, Issue 11, 2011, Pages 2193-2198

  Li, Yan ^a   Cao, Hongwei ^a   Wang, Ning ^a   Xiang, Yang ^a   Lu, Yongling ^a   Zhao, Kecen ^a   Zheng, Jiang ^a   Zhou, Hong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti inflammatory; CpG ODN; TLR9

Indexed keywords

ANTIINFLAMMATORY AGENT; CPG ODN C41; CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GENE; BIOINFORMATICS; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOSTIMULATION; MALE; MONOCYTE; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; CELL LINE; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; MONOCYTES; OLIGODEOXYRIBONUCLEOTIDES; PSEUDOMONAS AERUGINOSA; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951811761     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.042     Document Type: Article

References (25)

1. Krieg A.M. The role of CpG motifs in innate immunity. Curr Opin Immunol 2000, 12(February (1)):35-43.
2. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004, 5(Febraury (2)):190-198.
3. Hemmi H., Kaisho T., Takeda K., Akira S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003, 170(March (6)):3059-3064.
4. Klinman D.M., Takeshita F., Gursel I., Leifer C., Ishii K.J., Verthelyi D., et al. CpG DNA: recognition by and activation of monocytes. Microbes Infect 2002, 4(July (9)):897-901.
5. Zeuner R.A., Klinman D.M., Illei G., Yarboro C., Ishii K.J., Gursel M., et al. Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides. Rheumatology (Oxford) 2003, 42(April (4)):563-569.
6. Deng G.M., Zheng L., Chan F.K., Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005, 11(October (10)):1066-1072.
7. Zipris D., Lien E., Nair A., Xie J.X., Greiner D.L., Mordes J.P., et al. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007, 178(January (2)):693-701.
8. Nair A., Wolter T.R., Meyers A.J., Zipris D. Innate immune pathways in virus-induced autoimmune diabetes. Ann N Y Acad Sci 2008, 1150(December):139-142.
9. Van Eden W., Van Der Zee R., Van Kooten P., Berlo S.E., Cobelens P.M., Kavelaars A., et al. Balancing the immune system: Th1 and Th2. Ann Rheum Dis 2002, 61(November (Suppl. 2)):ii25-ii28.
10. Youn H.S., Lee J.Y., Fitzgerald K.A., Young H.A., Akira S., Hwang D.H. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005, 175(September (5)):3339-3346.
11. Wang L., Jiang W., Ding G., Cao H., Lu Y., Luo P., et al. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Int Immunopharmacol 2007, 7(May (5)):646-655.
12. Gursel M., Verthelyi D., Gursel I., Ishii K.J., Klinman D.M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukocyte Biol 2002, 71(May (5)):813-820.
13. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34(January (1)):251-262.
14. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001, 98(July (16)):9237-9242.
15. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z.K., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31(July (7)):2154-2163.
16. Blazar B.R., Krieg A.M., Taylor P.A. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001, 98(August (4)):1217-1225.
17. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003, 33(June (6)):1633-1641.
18. Yamamoto S., Kuramoto E., Shimada S., Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988, 79(July (7)):866-873.
19. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998, 16(July (11-12)):1216-1224.
20. Krieg A.M., Kline J.N. Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology 2000, 48(July (3)):303-305.
21. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61(March (3)):248-255.
22. Kollias G., Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002, 13(August-October (4-5)):315-321.
23. McDermott MF TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand) 2001, 47(June (4)):619-635.
24. Sun S., Rao N.L., Venable J., Thurmond R., Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007, 6(December (4)):223-235.
25. Linghua Z., Yong G., Xingshan T., Fengzhen Z. CpG oligodinucleotides induce strong humoral and cellular responses to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharmacol 2006, 6(March (3)):342-350.